Curanex Pipeline Expansion Targets New Diseases

Curanex is strategically expanding its drug development pipeline beyond its initial focus on inflammation and metabolic diseases. The company is advancing its Phyto-N program toward an Investigational New Drug (IND) application, signaling progress in its research efforts. Furthermore, Curanex has reported promising preclinical safety data, indicating a commitment to rigorous testing and development. This pipeline expansion suggests a broader therapeutic ambition for the company, aiming to address a wider range of medical conditions.